Table 5.
Pharmacokinetic parameters of the NRG solution (i.v. and i.n.) and NE formulation after i.n. administration.
| Formulation | Organ/Tissue | Cmax (ng/ml) | Tmax (h) | T1/2 (H) | Ke(h-1) | AUC0-480 (ng/ml∗h) | AUC0-infinity (ng/ml∗h) |
|---|---|---|---|---|---|---|---|
| NRG sol (i.n.) | Brain | 870.77 ± 5.4 | 2 | 6.84 ± 0.2 | 0.1 ± 0.003 | 3352.86 ± 8.9 | 5813.18 ± 9.2 |
| Blood | 775.44 ± 2.5 | 1 | 4.63 ± 0.4 | 0.14 ± 0.04 | 1919.734 ± 6.7 | 2554.17 ± 8.1 | |
|
| |||||||
| NRG NE (i.v.) | Brain | 381.67 ± 3.1 | 1 | 7.44 ± 0. 8 | 0.09 ± 0.003 | 1599.36 ± 4.5 | 3118.87 ± 11.2 |
| Blood | 2502.74 ± 4.2 | 0.5 | 3.13 ± 0.7 | 0.22 ± 0.007 | 7533.91 ± 4.5 | 9582.21 ± 7.8 | |
|
| |||||||
| NRG NE (i.n.) | Brain | 1148.64 ± 3.3 | 2 | 13.38 ± 1.1 | 0.05 ± 0.001 | 5345.13 ± 7.5 | 13543.23 ± 6.9 |
| Blood | 794.33 ± 7.1 | 2 | 10.4 ± 0.3 | 0.06 ± 0.02 | 3777.63 ± 5.3 | 8690.07 ± 8.5 | |
Pharmacokinetic parameters results clearly indicated that the NRG concentration is significantly higher in optimized formulation administered via i.n. (p<0.05) than that of administration of optimized formulation via i.v. and NRG solution via i.v. route.